Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Furmonertinib”

58 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 58 results

Early research (Phase 1)Study completedNCT03926182
What this trial is testing

Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers

Who this might be right for
Healthy Male Volunteers
Allist Pharmaceuticals, Inc. 16
Testing effectiveness (Phase 2)Looking for participantsNCT05379803
What this trial is testing

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06945705
What this trial is testing

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

Who this might be right for
NSCLC
Henan Cancer Hospital 146
Testing effectiveness (Phase 2)Study completedNCT05465343
What this trial is testing

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Who this might be right for
FurmonertinibEGFR-mutationNSCLC+1 more
Peking Union Medical College 24
Testing effectiveness (Phase 2)UnknownNCT05445310
What this trial is testing

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Peking Union Medical College Hospital 114
Early research (Phase 1)Study completedNCT03941340
What this trial is testing

Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

Who this might be right for
Healthy Male Volunteers
Allist Pharmaceuticals, Inc. 6
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Looking for participantsNCT07304739
What this trial is testing

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07517640
What this trial is testing

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 45
Not applicableNot Yet RecruitingNCT06117644
What this trial is testing

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 30
Testing effectiveness (Phase 2)UnknownNCT05821933
What this trial is testing

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Who this might be right for
NSCLC
RemeGen Co., Ltd. 106
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)UnknownNCT06339242
What this trial is testing

Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Who this might be right for
NSCLC
Jiangsu Province Nanjing Brain Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06585644
What this trial is testing

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Who this might be right for
Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 44
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT07548060
What this trial is testing

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital 25
Testing effectiveness (Phase 2)Study completedNCT06812871
What this trial is testing

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Sun Yat-sen University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07365410
What this trial is testing

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Brain MetastasesFurmonertinib+1 more
Tianjin Medical University Cancer Institute and Hospital 60
Next Page